HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In recent years, HDAC inhibitors have been approved for the treatment of cutaneous T-cell lymphoma (CTCL) (Khan and La Thangue, 2008), and their efficacy on solid cancers has been examined.